Fast and simple LC-MS/MS method for quantifying plasma voriconazole

Clinica Chimica Acta

Volumn 413, Issue 7-8, 2012, Pages 740-743

  Pauwels, Steven ^a   Vermeersch, Pieter ^a   Van Eldere, Johan ^a   Desmet, Koen ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Drug monitoring; HPLC; Tandem mass spectrometry; Voriconazole

Indexed keywords

REAGENT; VORICONAZOLE;

ARTICLE; BLOOD SAMPLING; CALIBRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LINEAR SYSTEM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MASS SPECTROMETRY; PRECIPITATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; TIME; TURNAROUND TIME; VALIDATION PROCESS;

ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 84857647472     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.01.008     Document Type: Article

References (32)

1. Walsh T.J., Anaissia E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:327-359.
2. Brüggemann R.J., Donnely J.P., Aarnoutse R.E., et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008, 30:403-411.
3. Pascual A., Calandra T., Bolay S., Buclin T., Bille J., Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201-211.
4. Ueda K., Nannya Y., Kumano K., et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009, 89:592-599.
5. Neely M., Rushing T., Kovacs A., Jelliffe R., Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010, 50:27-36.
6. Miyakis S., van Hal S.J., Ray J., Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010, 16:927-933.
7. Smith J., Safdar N., Knasinski V., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50:1570-1572.
8. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
9. Brüggemann R.J., van der Linden J.W., Verweij P.E., Burger D.M., Warris A. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 2011, 30:533-534.
10. Trifilio S., Pennick G., Pi J., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007, 109:1532-1535.
11. Matsumoto K., Ikawa K., Abematsu K., et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009, 34:91-94.
12. Zonios D.I., Gea-Banacloche J., Childs R., Bennett J.E. Hallucinations during voriconazole therapy. Clin Infect Dis 2008, 47:7-10.
13. Tan K., Brayshaw N., Tomaszewski K., Troke P., Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006, 46:235-243.
14. Imhof A., Schaer D.J., Schanz U., Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006, 136:739-742.
15. Ekiert R.J., Krzek J., Talik P. Chromatographic and electrophoretic techniques used in the analysis of triazole antifungal agents-a review. Talanta 2010, 82:1090-1100.
16. Péhourcq F., Jarry F., Bannwarth B. Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column. Biomed Chromatogr 2004, 18:719-722.
17. Pennick G.J., Clark M., Sutton D.A., Rinaldi M.G. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003, 47:2348-2350.
18. Wenk M., Droll A., Krahenbuhl S. Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. J Chromatogr B 2006, 832:313-316.
19. Khochschsorur G., Fruehwirth F., Zelzer S. Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum. Antimicrob Agents Chemother 2005, 49:3569-3571.
20. Chhun S., Rey E., Tran A., Lortholary O., Pons G., Julien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B 2007, 852:223-228.
21. Michael C., Teichert J., Preiss R. Determination of voriconazole in human plasma and saliva using high-performance liquid chromatography with fluorescence detection. J Chromatogr B 2008, 865:74-80.
22. Zhou L., Glickman R.D., Chen N., Sponsel W.E., Graybill J.R., Lam K.W. Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B 2002, 776:213-220.
23. Egle H., Trittler R., Konig A., Kummerer K. Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. J Chromatogr B 2005, 814:361-367.
24. Keevil B.G., Newman S., Lockhart S., Howard S.J., Moore C.B., Denning D.W. Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2004, 26:650-657.
25. Araujo B., Conrado D.J., Palma E.C., Costa T.D. Validation of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma. J Pharm Biomed Anal 2007, 44:985-990.
26. Vogeser M., Schiel X., Spohrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005, 43:730-734.
27. Farowski F., Cornely O.A., Vehreschild J.J., et al. Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010, 54:1815-1819.
28. Hafner V., Czock D., Burhenne J., et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010, 54:2596-2602.
29. Alffenaar J.W., Wessels A.M., van Hateren K., Greijdanus B., Kosterink J.G., Uges D.R. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B 2010, 878:39-44.
30. Xiong X., Duan J., Zhai S., Wang L., Lan X. Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS. Biosci Biotechnol Biochem 2010, 74:2151-2153.
31. Frazer C.G. Desirable standards of performance for therapeutic drug monitoring. Clin Chem 1987, 33:387-389.
32. Brüggeman R.J., Touw D.J., Aarnoutse R.E., Verweij P.E., Burger D.M. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009, 53:303-305.